According to a market analysis by Persistence Market Research, the global CAR T-cell treatment market had a value of US$ 1.2 billion in 2020 and is projected to grow to US$ 2.8 billion by 2031, representing a CAGR of 5.6% over the forecast period (2021-2031). CAR T-cell therapy, a subset of T-cell therapy or a method of treating cancer cells, commands around 27% of the market for T-cell therapy as a whole.

The development of CAR T-cells for therapeutic applications is anticipated to be fueled by the rising incidence of cancer. Artificial T-cell receptors may be used in the therapy of a number of malignancies, as has been generally accepted.

Request for Free Sample Copy@ https://www.persistencemarketresearch.com/samples/28264

The process of creating CAR T-cells starts with the patient’s T-cells being removed, followed by apheresis, and then the patient’s T-cells are sent to the production facility. CAR T-cell production is now limited to a few number of factories, most of which are found in the United States and Europe. According to Persistence Market Research, the global CAR T-cell therapy market will grow at a CAGR of 5.6% from 2017 to 2031. This growth is primarily attributable to the growing number of CAR T-cell clinical trials, the involvement of key players in manufacturing, and the rising demand for cancer therapy.

Get up to 20% discount on Full Report Purchase @ https://www.persistencemarketresearch.com/checkout/28264

Car T-Cell Therapy Market Industry Research by Category

Product

• • Yescarta (axicabtagene ciloleucel)
  • Kymriah (tisagenlecleucel)
  • JCAR017 (lisocabtagene maraleucel)
  • bb2121

Indication

• • Relapsed Large B-cell Lymphoma
  • Acute Lymphoblastic Leukemia (ALL)
  • Multiple Myeloma

End User

• • Car T-Cell Therapy at Hospitals
  • Car T-Cell Therapy at Cancer Treatment Centers

Request For Customization @ https://www.persistencemarketresearch.com/request-customization/28264

Competitive Landscape

Companies providing CAR T-cell therapy are vigorously seeking to strengthen their position through collaborations, approvals, acquisitions, and agreements with established as well as emerging market players.

• • In May 2019, a Japanese government panel approved Novartis to sell Kymriah in Japan for $306,000 for treating the young population with acute lymphoblastic leukaemia (ALL) and the adult population with diffuse large B-cell lymphoma (DLBCL).
  • In August 2017, Gilead Science acquired Kite Pharma Inc., an industry leader in the emerging field of cell therapy.
  • In December 2017, Gilead Science acquired Cell Design Labs Inc. This acquisition benefits Gilead in the attainment of new technology platforms that will enhance research & development efforts in cellular therapy.

Companies

• • Novartis AG
  • Gilead Sciences Inc.
  • Celgene Corporation
  • bluebird bio, Inc.

Category-wise Insights
Why is Demand for Yescarta (axicabtagene ciloleucel) Rising Rapidly?

• • In terms of product, Yescarta (axicabtagene ciloleucel) holds a high share of over 57% in 2021. Yescarta (axicabtagene ciloleucel) is a treatment for large B-cell lymphoma, which is used when conventional treatment methods do not work effectively.
  • Large B-Cell Lymphoma Holds highest Market Share by Indication?
  • In terms of indication, relapsed large B-cell lymphoma holds approximately 90% market share in 2021. This is a condition when the lymphoma does not respond to treatment or when the response to treatment lasts for a short period.

About Us

Persistence Market Research (PMR), as a 3rd-party research organization, does operate through an exclusive amalgamation of market research and data analytics for helping businesses ride high, irrespective of the turbulence faced on the account of financial/natural crunches.

Contact Us

Persistence market research
Address – 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com